Stock SNOA SONOMA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Sonoma Pharmaceuticals, Inc.

Equities

SNOA

US83558L2043

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
0.156 USD +1.89% Intraday chart for Sonoma Pharmaceuticals, Inc. -1.89% -13.53%
Feb. 08 Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jan. 23 Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use CI

Evolution of the average Target Price on Sonoma Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

54cb533f.p6nqcQaLTI09Wqya_7MVTFU8A-VSHeMgQ2E7srgrcpA.3eOzG2y9FLsIKeXgquB6FgcOYdElcKpHOSBQxPoSCPH93IMIauchx3odmA~776e72e3c009fb0649effd62932fabd8

Analyst Recommendations on Sonoma Pharmaceuticals, Inc.

Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.156
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sonoma Pharmaceuticals, Inc.

Ladenburg Thalmann

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SNOA Stock
  4. Consensus Sonoma Pharmaceuticals, Inc.